CJC-1295 No DAC: What Researchers Need to Know in 2026

Among the growth hormone-modulating peptides that have attracted serious scientific attention, CJC-1295 No DAC occupies a unique position. It mimics the body’s own signaling system with a precision that the DAC version cannot, producing sharp, physiological-style GH pulses rather than a sustained bleed. For researchers focused on GH axis dynamics, body composition, and recovery biology, this distinction matters enormously.

What Is CJC-1295 No DAC?

CJC-1295 No DAC — also referred to as Modified GRF 1-29 (Mod GRF 1-29) — is a synthetic analog of growth hormone-releasing hormone (GHRH). It is a 29-amino-acid peptide engineered with four amino acid substitutions that significantly improve its stability over native GHRH(1-29), known as sermorelin. Crucially, it lacks the Drug Affinity Complex (DAC) found in the CJC-1295 DAC version, which means it does not bind to albumin in the bloodstream. The result: a half-life of approximately 30 minutes, producing a clean, pulsatile GH release pattern that closely mirrors natural physiology.

This pulsatility is not a limitation — it is the mechanism. Natural GH secretion is episodic, and the downstream anabolic and lipolytic effects of GH depend substantially on that pulse architecture. CJC-1295 No DAC reproduces that architecture in a research context.

Research Overview

According to PubMed, CJC-1295 and related GHRH analogs have been examined across multiple research domains. A 2026 narrative review published in Frontiers in Endocrinology by Dominikowski et al. (DOI: 10.3389/fendo.2026.1822475) provides a comprehensive comparison of GH-modulating peptides, stratifying evidence tiers from regulatory-grade randomized trial data down to compounds with no published human studies. CJC-1295 without DAC is characterized as a GHRH analog producing pulsatile GH release, with documented pharmacokinetic and pharmacodynamic profiles.

A 2026 critical review in the Journal of Sports Medicine and Physical Fitness by Coutinho et al. (DOI: 10.23736/S0022-4707.26.17773-1) evaluated GH secretagogues and GHRH analogs — including CJC-1295 — in the context of recreational and professional sport, noting their promotion for muscle growth, fat metabolism, and recovery, while highlighting the gap between therapeutic evidence and the supraphysiological dosing patterns encountered in bodybuilding communities.

CJC-1295 has also attracted attention from anti-doping researchers. Work published in the Journal of Mass Spectrometry (Thomas et al., 2024, DOI: 10.1002/jms.4996) and in Analytical Biochemistry (Cristea et al., 2023, DOI: 10.1016/j.ab.2023.115336) has established validated detection methods in urine, confirming that the compound is prohibited under WADA regulations and actively screened for in elite sport.

For additional community discussion, researchers frequently consult the r/Peptides subreddit, where firsthand accounts of protocols, dosing timing, and combination strategies are widely documented.

Potential Benefits Studied

Amplified GH pulse amplitude: CJC-1295 No DAC acts on GHRH receptors in the pituitary to increase the size of endogenous GH pulses without suppressing the normal GH rhythm.
Downstream IGF-1 elevation: Increased GH secretion triggers hepatic IGF-1 production, the key mediator of anabolic effects including muscle protein synthesis and satellite cell activation.
Lipolytic activity: GH has direct lipolytic effects on adipocytes, particularly visceral fat depots, making GH axis modulation of interest in body composition research.
Recovery and tissue repair: The GH/IGF-1 axis plays a documented role in connective tissue maintenance, collagen synthesis, and recovery from training-induced micro-damage.
Sleep quality enhancement: GH secretion peaks during slow-wave sleep stages; research subjects administering GHRH analogs before sleep have reported improvements in sleep depth and recovery quality.
Preserved pulsatility vs. continuous GH exposure: Unlike exogenous GH, which creates sustained elevations that can desensitize receptors and increase IGF-1 to supraphysiological ranges, GHRH analogs preserve the pulsatile signaling architecture, which may offer a more favorable safety profile in research contexts.

Dosage & Administration

CJC-1295 No DAC is an injectable peptide, administered subcutaneously. In research protocols, dosing typically falls between 100–300 mcg per injection, administered 2–3 times daily to maintain pulsatile GH stimulation. The most studied timing windows are immediately pre-sleep and pre-training, when endogenous GH pulses are naturally highest and pituitary sensitivity is elevated. Research commonly pairs it with a growth hormone secretagogue (GHRP) such as ipamorelin to synergistically amplify GH release — the GHRH analog sets the pulse, and the secretagogue amplifies it. Cycle lengths in the literature range from 8 to 16 weeks, with periodic breaks observed in longitudinal self-administration reports.

Where to Find It

CJC-1295 No DAC is available for research purposes at combatresearch.is. All products are supplied for laboratory and research use only.

Conclusion

CJC-1295 No DAC represents one of the most mechanistically sophisticated tools available for GH axis research. Its ability to amplify natural GH pulses — without disrupting the pulsatile architecture that governs downstream receptor signaling — distinguishes it from both exogenous GH and the longer-acting DAC variant. For researchers interested in growth hormone biology, body composition dynamics, or recovery physiology, the evidence base and community of practitioners surrounding this compound make it one of the most extensively documented GHRH analogs in circulation.

Disclaimer: This article is for educational and research purposes only. CJC-1295 No DAC is not approved by the FDA for human use. This content does not constitute medical advice. Consult a qualified healthcare professional before considering any peptide protocol.